Impact of the clinically approved BTK inhibitors on the conformation of full-length BTK and analysis of the development ...
Ibrutinib (IMBRUVICA®), has revolutionized the treatment of the B cell malignancy, CLL [1]. Ibrutinib is a covalent active site inhibitor of the multi-domain B-cell kinase, BTK (Fig. 1a), that was first approved by the FDA in 2013 [2]. Inhibition of BTK …